CA2563017C - Substituted cyclohexylacetic acid derivatives - Google Patents
Substituted cyclohexylacetic acid derivatives Download PDFInfo
- Publication number
- CA2563017C CA2563017C CA2563017A CA2563017A CA2563017C CA 2563017 C CA2563017 C CA 2563017C CA 2563017 A CA2563017 A CA 2563017A CA 2563017 A CA2563017 A CA 2563017A CA 2563017 C CA2563017 C CA 2563017C
- Authority
- CA
- Canada
- Prior art keywords
- dimethylamino
- hydrochloride
- acetamide
- phenyl
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- LJOODBDWMQKMFB-UHFFFAOYSA-N cyclohexylacetic acid Chemical class OC(=O)CC1CCCCC1 LJOODBDWMQKMFB-UHFFFAOYSA-N 0.000 title claims description 62
- 150000001875 compounds Chemical class 0.000 claims abstract description 67
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 41
- 239000003814 drug Substances 0.000 claims abstract description 35
- 208000002193 Pain Diseases 0.000 claims abstract description 34
- 230000036407 pain Effects 0.000 claims abstract description 21
- 230000003444 anaesthetic effect Effects 0.000 claims abstract description 13
- 229940005483 opioid analgesics Drugs 0.000 claims abstract description 13
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims abstract description 12
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 10
- 230000001771 impaired effect Effects 0.000 claims abstract description 10
- 230000001777 nootropic effect Effects 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 230000000694 effects Effects 0.000 claims abstract description 9
- 208000000094 Chronic Pain Diseases 0.000 claims abstract description 7
- 206010012335 Dependence Diseases 0.000 claims abstract description 7
- 208000004880 Polyuria Diseases 0.000 claims abstract description 7
- 238000011260 co-administration Methods 0.000 claims abstract description 7
- 230000035619 diuresis Effects 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 7
- 239000002858 neurotransmitter agent Substances 0.000 claims abstract description 7
- 230000028327 secretion Effects 0.000 claims abstract description 7
- 208000009132 Catalepsy Diseases 0.000 claims abstract description 6
- 206010012735 Diarrhoea Diseases 0.000 claims abstract description 6
- 206010046543 Urinary incontinence Diseases 0.000 claims abstract description 6
- 206010047853 Waxy flexibility Diseases 0.000 claims abstract description 6
- 230000001154 acute effect Effects 0.000 claims abstract description 6
- 208000005298 acute pain Diseases 0.000 claims abstract description 6
- 208000022531 anorexia Diseases 0.000 claims abstract description 6
- 230000002082 anti-convulsion Effects 0.000 claims abstract description 6
- 206010061428 decreased appetite Diseases 0.000 claims abstract description 6
- 206010015037 epilepsy Diseases 0.000 claims abstract description 6
- 230000037406 food intake Effects 0.000 claims abstract description 6
- 235000012631 food intake Nutrition 0.000 claims abstract description 6
- 230000008991 intestinal motility Effects 0.000 claims abstract description 6
- 230000033001 locomotion Effects 0.000 claims abstract description 6
- 239000003158 myorelaxant agent Substances 0.000 claims abstract description 6
- 208000004296 neuralgia Diseases 0.000 claims abstract description 6
- 230000002981 neuropathic effect Effects 0.000 claims abstract description 6
- 208000021722 neuropathic pain Diseases 0.000 claims abstract description 6
- 239000000014 opioid analgesic Substances 0.000 claims abstract description 6
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 5
- 206010006895 Cachexia Diseases 0.000 claims abstract description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 5
- 206010020772 Hypertension Diseases 0.000 claims abstract description 5
- 208000001953 Hypotension Diseases 0.000 claims abstract description 5
- 208000020358 Learning disease Diseases 0.000 claims abstract description 5
- 208000026139 Memory disease Diseases 0.000 claims abstract description 5
- 208000019695 Migraine disease Diseases 0.000 claims abstract description 5
- 208000008589 Obesity Diseases 0.000 claims abstract description 5
- 208000003251 Pruritus Diseases 0.000 claims abstract description 5
- 206010039966 Senile dementia Diseases 0.000 claims abstract description 5
- 201000001880 Sexual dysfunction Diseases 0.000 claims abstract description 5
- 208000009205 Tinnitus Diseases 0.000 claims abstract description 5
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 5
- 230000002950 deficient Effects 0.000 claims abstract description 5
- 208000035475 disorder Diseases 0.000 claims abstract description 5
- 230000036543 hypotension Effects 0.000 claims abstract description 5
- 201000003723 learning disability Diseases 0.000 claims abstract description 5
- 230000003137 locomotive effect Effects 0.000 claims abstract description 5
- 206010027599 migraine Diseases 0.000 claims abstract description 5
- 235000020824 obesity Nutrition 0.000 claims abstract description 5
- 231100000872 sexual dysfunction Toxicity 0.000 claims abstract description 5
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 5
- 231100000886 tinnitus Toxicity 0.000 claims abstract description 5
- 230000009278 visceral effect Effects 0.000 claims abstract description 5
- 208000009935 visceral pain Diseases 0.000 claims abstract description 5
- 208000007848 Alcoholism Diseases 0.000 claims abstract 4
- 206010013654 Drug abuse Diseases 0.000 claims abstract 4
- 206010001584 alcohol abuse Diseases 0.000 claims abstract 4
- 208000025746 alcohol use disease Diseases 0.000 claims abstract 4
- 201000009032 substance abuse Diseases 0.000 claims abstract 4
- 208000011117 substance-related disease Diseases 0.000 claims abstract 4
- -1 benzodioxolanyl Chemical group 0.000 claims description 275
- 239000000203 mixture Substances 0.000 claims description 209
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 102
- 150000003839 salts Chemical class 0.000 claims description 50
- 239000002585 base Substances 0.000 claims description 49
- 229920006395 saturated elastomer Polymers 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 32
- 125000003118 aryl group Chemical group 0.000 claims description 28
- 230000008569 process Effects 0.000 claims description 22
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 19
- 239000003054 catalyst Substances 0.000 claims description 19
- 125000001072 heteroaryl group Chemical group 0.000 claims description 19
- 125000004076 pyridyl group Chemical group 0.000 claims description 19
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 18
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 16
- 125000001544 thienyl group Chemical group 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 15
- 125000001624 naphthyl group Chemical group 0.000 claims description 15
- 125000002541 furyl group Chemical group 0.000 claims description 14
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 13
- XUYJLQHKOGNDPB-UHFFFAOYSA-N carboxymethyl phosphonic acid Natural products OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 claims description 13
- 125000001041 indolyl group Chemical group 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 12
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 11
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 11
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 11
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 11
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 10
- 150000001768 cations Chemical class 0.000 claims description 10
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 9
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 9
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 9
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 8
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 150000001412 amines Chemical class 0.000 claims description 7
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 7
- 150000003254 radicals Chemical class 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims description 6
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims description 6
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 6
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 6
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims description 6
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 6
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 6
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims description 6
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 6
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims description 6
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 6
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 6
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 6
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 6
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 6
- CJYQKUZVHJLIGS-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-(3-fluorophenyl)cyclohexylidene]-n-[2-(1h-indol-3-yl)ethyl]acetamide;hydrochloride Chemical compound Cl.C1CC(=CC(=O)NCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC(F)=C1 CJYQKUZVHJLIGS-UHFFFAOYSA-N 0.000 claims description 5
- QQPIWEXJHHUYSU-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-(4-fluorophenyl)cyclohexylidene]-n-(3-phenylpropyl)acetamide;hydrochloride Chemical compound Cl.C1CC(N(C)C)(C=2C=CC(F)=CC=2)CCC1=CC(=O)NCCCC1=CC=CC=C1 QQPIWEXJHHUYSU-UHFFFAOYSA-N 0.000 claims description 5
- ZUTROUQLHSKEOI-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-(4-fluorophenyl)cyclohexylidene]-n-[2-(1h-indol-3-yl)ethyl]acetamide;hydrochloride Chemical compound Cl.C1CC(=CC(=O)NCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=C(F)C=C1 ZUTROUQLHSKEOI-UHFFFAOYSA-N 0.000 claims description 5
- IQFHGPWESACTJS-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexylidene]-n-[3-(1h-indol-3-yl)propyl]acetamide;hydrochloride Chemical compound Cl.C1CC(=CC(=O)NCCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC=C1 IQFHGPWESACTJS-UHFFFAOYSA-N 0.000 claims description 5
- XVNCJNDEVIOODN-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexylidene]-n-[5-(1h-indol-3-yl)pentyl]acetamide;hydrochloride Chemical compound Cl.C1CC(=CC(=O)NCCCCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC=C1 XVNCJNDEVIOODN-UHFFFAOYSA-N 0.000 claims description 5
- 150000005840 aryl radicals Chemical group 0.000 claims description 5
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims description 5
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 5
- XFTPQJQBMJHZKF-UHFFFAOYSA-N methyl 2-[[2-[4-(dimethylamino)-4-phenylcyclohexylidene]acetyl]amino]-3-(1h-indol-3-yl)propanoate;hydrochloride Chemical compound Cl.C=1NC2=CC=CC=C2C=1CC(C(=O)OC)NC(=O)C=C(CC1)CCC1(N(C)C)C1=CC=CC=C1 XFTPQJQBMJHZKF-UHFFFAOYSA-N 0.000 claims description 5
- BBPOBTJKFXYUSK-UHFFFAOYSA-N n-benzyl-2-[4-(dimethylamino)-4-phenylcyclohexylidene]acetamide;hydrochloride Chemical compound Cl.C1CC(N(C)C)(C=2C=CC=CC=2)CCC1=CC(=O)NCC1=CC=CC=C1 BBPOBTJKFXYUSK-UHFFFAOYSA-N 0.000 claims description 5
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical group [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 5
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims description 4
- JOKLEJREDCNIKD-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-(3-fluorophenyl)cyclohexyl]-n-[1-(1h-indol-3-yl)propan-2-yl]acetamide;hydrochloride Chemical compound Cl.C=1NC2=CC=CC=C2C=1CC(C)NC(=O)CC(CC1)CCC1(N(C)C)C1=CC=CC(F)=C1 JOKLEJREDCNIKD-UHFFFAOYSA-N 0.000 claims description 4
- RXQWCUNKUKVDHD-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-(3-fluorophenyl)cyclohexylidene]-n-(3-phenylpropyl)acetamide;hydrochloride Chemical compound Cl.C1CC(N(C)C)(C=2C=C(F)C=CC=2)CCC1=CC(=O)NCCCC1=CC=CC=C1 RXQWCUNKUKVDHD-UHFFFAOYSA-N 0.000 claims description 4
- FCWZPJHDDUOKHF-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-(3-fluorophenyl)cyclohexylidene]-n-[1-(1h-indol-3-yl)propan-2-yl]acetamide Chemical compound C=1NC2=CC=CC=C2C=1CC(C)NC(=O)C=C(CC1)CCC1(N(C)C)C1=CC=CC(F)=C1 FCWZPJHDDUOKHF-UHFFFAOYSA-N 0.000 claims description 4
- VIFMOYOHMQLGAS-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]-n-(2-phenylethyl)acetamide;hydrochloride Chemical compound Cl.C1CC(N(C)C)(C=2C=CC=CC=2)CCC1CC(=O)NCCC1=CC=CC=C1 VIFMOYOHMQLGAS-UHFFFAOYSA-N 0.000 claims description 4
- VOQSWHYBHNXFFU-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]-n-(4-phenylbutyl)acetamide;hydrochloride Chemical compound Cl.C1CC(N(C)C)(C=2C=CC=CC=2)CCC1CC(=O)NCCCCC1=CC=CC=C1 VOQSWHYBHNXFFU-UHFFFAOYSA-N 0.000 claims description 4
- CUJYIQNNCFPCIE-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]-n-[2-(1h-indol-3-yl)ethyl]acetamide;hydrochloride Chemical compound Cl.C1CC(CC(=O)NCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC=C1 CUJYIQNNCFPCIE-UHFFFAOYSA-N 0.000 claims description 4
- YLKSRBBBJYTVKJ-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]-n-[3-(1h-indol-3-yl)propyl]acetamide;hydrochloride Chemical compound Cl.C1CC(CC(=O)NCCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC=C1 YLKSRBBBJYTVKJ-UHFFFAOYSA-N 0.000 claims description 4
- XKTKPRVXGIGROW-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]-n-[4-(1h-indol-3-yl)butyl]acetamide;hydrochloride Chemical compound Cl.C1CC(CC(=O)NCCCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC=C1 XKTKPRVXGIGROW-UHFFFAOYSA-N 0.000 claims description 4
- LULRVVPEJPXSTK-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]-n-[5-(1h-indol-3-yl)pentyl]acetamide;hydrochloride Chemical compound Cl.C1CC(CC(=O)NCCCCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC=C1 LULRVVPEJPXSTK-UHFFFAOYSA-N 0.000 claims description 4
- BRQVUJAVGATRDQ-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexylidene]-n-(1h-indol-3-ylmethyl)acetamide;hydrochloride Chemical compound Cl.C1CC(=CC(=O)NCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC=C1 BRQVUJAVGATRDQ-UHFFFAOYSA-N 0.000 claims description 4
- PLHMGPYQBIEXPI-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexylidene]-n-(2-phenylethyl)acetamide;hydrochloride Chemical compound Cl.C1CC(N(C)C)(C=2C=CC=CC=2)CCC1=CC(=O)NCCC1=CC=CC=C1 PLHMGPYQBIEXPI-UHFFFAOYSA-N 0.000 claims description 4
- SVHZXTOUDQHWIH-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexylidene]-n-(3-phenylpropyl)acetamide;hydrochloride Chemical compound Cl.C1CC(N(C)C)(C=2C=CC=CC=2)CCC1=CC(=O)NCCCC1=CC=CC=C1 SVHZXTOUDQHWIH-UHFFFAOYSA-N 0.000 claims description 4
- RTBXXECSCDIAOA-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexylidene]-n-(4-phenylbutyl)acetamide;hydrochloride Chemical compound Cl.C1CC(N(C)C)(C=2C=CC=CC=2)CCC1=CC(=O)NCCCCC1=CC=CC=C1 RTBXXECSCDIAOA-UHFFFAOYSA-N 0.000 claims description 4
- GDICGRWNXYWJSE-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexylidene]-n-[(4-fluorophenyl)methyl]acetamide;hydrochloride Chemical compound Cl.C1CC(N(C)C)(C=2C=CC=CC=2)CCC1=CC(=O)NCC1=CC=C(F)C=C1 GDICGRWNXYWJSE-UHFFFAOYSA-N 0.000 claims description 4
- DASCBEIQPSWVQR-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexylidene]-n-[2-(4-fluorophenyl)ethyl]acetamide;hydrochloride Chemical compound Cl.C1CC(N(C)C)(C=2C=CC=CC=2)CCC1=CC(=O)NCCC1=CC=C(F)C=C1 DASCBEIQPSWVQR-UHFFFAOYSA-N 0.000 claims description 4
- NSDOZTVPWBRTLG-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexylidene]-n-[4-(1h-indol-3-yl)butyl]acetamide;hydrochloride Chemical compound Cl.C1CC(=CC(=O)NCCCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC=C1 NSDOZTVPWBRTLG-UHFFFAOYSA-N 0.000 claims description 4
- JMILVWBBDLLQBD-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexylidene]-n-[6-(1h-indol-3-yl)hexyl]acetamide;hydrochloride Chemical compound Cl.C1CC(=CC(=O)NCCCCCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC=C1 JMILVWBBDLLQBD-UHFFFAOYSA-N 0.000 claims description 4
- LWCOSZMDBZTTMB-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-pyridin-2-ylcyclohexylidene]-n-(3-phenylpropyl)acetamide;hydrochloride Chemical compound Cl.C1CC(N(C)C)(C=2N=CC=CC=2)CCC1=CC(=O)NCCCC1=CC=CC=C1 LWCOSZMDBZTTMB-UHFFFAOYSA-N 0.000 claims description 4
- VOYLFEWMTNNWFF-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-pyridin-2-ylcyclohexylidene]-n-[2-(1h-indol-3-yl)ethyl]acetamide;hydrochloride Chemical compound Cl.C1CC(=CC(=O)NCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC=N1 VOYLFEWMTNNWFF-UHFFFAOYSA-N 0.000 claims description 4
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims description 4
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 claims description 4
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 4
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 150000001718 carbodiimides Chemical group 0.000 claims description 4
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 4
- 229910052763 palladium Inorganic materials 0.000 claims description 4
- 229910052697 platinum Inorganic materials 0.000 claims description 4
- 229910052703 rhodium Inorganic materials 0.000 claims description 4
- 239000010948 rhodium Substances 0.000 claims description 4
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims description 4
- QRLCIWHWUJFNRB-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-(4-fluorophenyl)cyclohexyl]-n-(3-phenylpropyl)acetamide;hydrochloride Chemical compound Cl.C1CC(N(C)C)(C=2C=CC(F)=CC=2)CCC1CC(=O)NCCCC1=CC=CC=C1 QRLCIWHWUJFNRB-UHFFFAOYSA-N 0.000 claims description 3
- NLOJFZZRPQCNMS-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-(4-fluorophenyl)cyclohexylidene]-n-[1-(1h-indol-3-yl)propan-2-yl]acetamide;hydrochloride Chemical compound Cl.C=1NC2=CC=CC=C2C=1CC(C)NC(=O)C=C(CC1)CCC1(N(C)C)C1=CC=C(F)C=C1 NLOJFZZRPQCNMS-UHFFFAOYSA-N 0.000 claims description 3
- AGZSYTLVKPEGPU-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]-n-(4-methoxyphenyl)acetamide;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1NC(=O)CC1CCC(C=2C=CC=CC=2)(N(C)C)CC1 AGZSYTLVKPEGPU-UHFFFAOYSA-N 0.000 claims description 3
- VFVKWRQVGDJTJB-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]-n-[1-(1h-indol-3-yl)propan-2-yl]acetamide;hydrochloride Chemical compound Cl.C=1NC2=CC=CC=C2C=1CC(C)NC(=O)CC(CC1)CCC1(N(C)C)C1=CC=CC=C1 VFVKWRQVGDJTJB-UHFFFAOYSA-N 0.000 claims description 3
- JHZAXZMVHGRBBU-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]-n-[6-(1h-indol-3-yl)hexyl]acetamide;hydrochloride Chemical compound Cl.C1CC(CC(=O)NCCCCCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC=C1 JHZAXZMVHGRBBU-UHFFFAOYSA-N 0.000 claims description 3
- XXKVRGSLYDVPOC-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexylidene]-n-[1-(1h-indol-3-yl)propan-2-yl]acetamide;hydrochloride Chemical compound Cl.C=1NC2=CC=CC=C2C=1CC(C)NC(=O)C=C(CC1)CCC1(N(C)C)C1=CC=CC=C1 XXKVRGSLYDVPOC-UHFFFAOYSA-N 0.000 claims description 3
- MUEBBAIDUIQUQS-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexylidene]-n-[[2-(trifluoromethyl)phenyl]methyl]acetamide;hydrochloride Chemical compound Cl.C1CC(N(C)C)(C=2C=CC=CC=2)CCC1=CC(=O)NCC1=CC=CC=C1C(F)(F)F MUEBBAIDUIQUQS-UHFFFAOYSA-N 0.000 claims description 3
- KMTAMTDLIBHTFP-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-pyridin-2-ylcyclohexyl]-n-(3-phenylpropyl)acetamide;hydrochloride Chemical compound Cl.C1CC(N(C)C)(C=2N=CC=CC=2)CCC1CC(=O)NCCCC1=CC=CC=C1 KMTAMTDLIBHTFP-UHFFFAOYSA-N 0.000 claims description 3
- HCMXPFDHWXHWDG-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-pyridin-2-ylcyclohexyl]-n-[2-(1h-indol-3-yl)ethyl]acetamide;hydrochloride Chemical compound Cl.C1CC(CC(=O)NCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC=N1 HCMXPFDHWXHWDG-UHFFFAOYSA-N 0.000 claims description 3
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 125000005879 dioxolanyl group Chemical group 0.000 claims description 3
- 238000010931 ester hydrolysis Methods 0.000 claims description 3
- 125000003914 fluoranthenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC=C4C1=C23)* 0.000 claims description 3
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 3
- 238000005984 hydrogenation reaction Methods 0.000 claims description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000002524 organometallic group Chemical group 0.000 claims description 3
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 3
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical group [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 claims description 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000000335 thiazolyl group Chemical group 0.000 claims description 3
- UTDGQDYHKXTLEX-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-(3-fluorophenyl)cyclohexyl]-n-(3-phenylpropyl)acetamide;hydrochloride Chemical compound Cl.C1CC(N(C)C)(C=2C=C(F)C=CC=2)CCC1CC(=O)NCCCC1=CC=CC=C1 UTDGQDYHKXTLEX-UHFFFAOYSA-N 0.000 claims description 2
- ZGELMQCVXODCBP-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-(3-fluorophenyl)cyclohexyl]-n-[2-(1h-indol-3-yl)ethyl]acetamide;hydrochloride Chemical compound Cl.C1CC(CC(=O)NCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC(F)=C1 ZGELMQCVXODCBP-UHFFFAOYSA-N 0.000 claims description 2
- JKHUAAVDCKVKTP-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]-n-(3-phenylpropyl)acetamide;hydrochloride Chemical compound Cl.C1CC(N(C)C)(C=2C=CC=CC=2)CCC1CC(=O)NCCCC1=CC=CC=C1 JKHUAAVDCKVKTP-UHFFFAOYSA-N 0.000 claims description 2
- KMNXHAOISILVMZ-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]-n-(4-methylphenyl)acetamide;hydrochloride Chemical compound Cl.C1CC(N(C)C)(C=2C=CC=CC=2)CCC1CC(=O)NC1=CC=C(C)C=C1 KMNXHAOISILVMZ-UHFFFAOYSA-N 0.000 claims description 2
- NCEQIUZJBKYRJI-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]-n-[[2-(trifluoromethyl)phenyl]methyl]acetamide;hydrochloride Chemical compound Cl.C1CC(N(C)C)(C=2C=CC=CC=2)CCC1CC(=O)NCC1=CC=CC=C1C(F)(F)F NCEQIUZJBKYRJI-UHFFFAOYSA-N 0.000 claims description 2
- BRNXKDIARBAMHE-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexylidene]-n-(4-fluorophenyl)acetamide;hydrochloride Chemical compound Cl.C1CC(N(C)C)(C=2C=CC=CC=2)CCC1=CC(=O)NC1=CC=C(F)C=C1 BRNXKDIARBAMHE-UHFFFAOYSA-N 0.000 claims description 2
- QGWRZBSRUFMXQA-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexylidene]-n-[2-(1h-indol-3-yl)ethyl]acetamide Chemical compound C1CC(=CC(=O)NCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC=C1 QGWRZBSRUFMXQA-UHFFFAOYSA-N 0.000 claims description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 2
- 125000005605 benzo group Chemical group 0.000 claims description 2
- YGXXCZGXWASXIZ-UHFFFAOYSA-N methyl 2-[[2-[4-(dimethylamino)-4-phenylcyclohexyl]acetyl]amino]-3-(1h-indol-3-yl)propanoate;hydrochloride Chemical compound Cl.C=1NC2=CC=CC=C2C=1CC(C(=O)OC)NC(=O)CC(CC1)CCC1(N(C)C)C1=CC=CC=C1 YGXXCZGXWASXIZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000001979 organolithium group Chemical group 0.000 claims description 2
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 4
- 101100439664 Arabidopsis thaliana CHR8 gene Proteins 0.000 claims 2
- IQQFJQICHFMCJD-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-(4-fluorophenyl)cyclohexyl]-n-[1-(1h-indol-3-yl)propan-2-yl]acetamide;hydrochloride Chemical compound Cl.C=1NC2=CC=CC=C2C=1CC(C)NC(=O)CC(CC1)CCC1(N(C)C)C1=CC=C(F)C=C1 IQQFJQICHFMCJD-UHFFFAOYSA-N 0.000 claims 1
- VSILQARCFWRDTB-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-(4-fluorophenyl)cyclohexyl]-n-[2-(1h-indol-3-yl)ethyl]acetamide;hydrochloride Chemical compound Cl.C1CC(CC(=O)NCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=C(F)C=C1 VSILQARCFWRDTB-UHFFFAOYSA-N 0.000 claims 1
- KMLPEYHLAKSCGX-UHFFFAOYSA-N 2-aminocyclohexan-1-one Chemical class NC1CCCCC1=O KMLPEYHLAKSCGX-UHFFFAOYSA-N 0.000 claims 1
- JTMQTEJTPLGANJ-UHFFFAOYSA-N Cl.CN(C1(CCC(CC1)CC(=O)NC1=CC=C(C=C1)F)C1=CC=CC=C1)C.Cl.CN(C1(CCC(CC1)CC(=O)NC1=CC=CC=C1)C1=CC=CC=C1)C.Cl Chemical compound Cl.CN(C1(CCC(CC1)CC(=O)NC1=CC=C(C=C1)F)C1=CC=CC=C1)C.Cl.CN(C1(CCC(CC1)CC(=O)NC1=CC=CC=C1)C1=CC=CC=C1)C.Cl JTMQTEJTPLGANJ-UHFFFAOYSA-N 0.000 claims 1
- 239000007818 Grignard reagent Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- DCZFGQYXRKMVFG-UHFFFAOYSA-N cyclohexane-1,4-dione Chemical class O=C1CCC(=O)CC1 DCZFGQYXRKMVFG-UHFFFAOYSA-N 0.000 claims 1
- 239000012024 dehydrating agents Substances 0.000 claims 1
- 150000004795 grignard reagents Chemical group 0.000 claims 1
- 239000000243 solution Substances 0.000 description 231
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 141
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 130
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 114
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 112
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 105
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 104
- 239000007787 solid Substances 0.000 description 99
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 82
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 75
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 74
- 239000000047 product Substances 0.000 description 69
- 239000004202 carbamide Substances 0.000 description 65
- 239000000706 filtrate Substances 0.000 description 65
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 52
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 44
- 239000011541 reaction mixture Substances 0.000 description 44
- 229910052786 argon Inorganic materials 0.000 description 41
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 38
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 37
- 239000008346 aqueous phase Substances 0.000 description 34
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 33
- 238000004587 chromatography analysis Methods 0.000 description 31
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- 239000000741 silica gel Substances 0.000 description 29
- 229910002027 silica gel Inorganic materials 0.000 description 29
- 239000012043 crude product Substances 0.000 description 26
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- 239000003921 oil Substances 0.000 description 21
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 16
- QAEPYUHNQQHKRZ-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexylidene]acetic acid;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C1(N(C)C)CCC(=CC(O)=O)CC1 QAEPYUHNQQHKRZ-UHFFFAOYSA-N 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 13
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 12
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 10
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 9
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 9
- OJLXVKAPPQTUIZ-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]acetic acid;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C1(N(C)C)CCC(CC(O)=O)CC1 OJLXVKAPPQTUIZ-UHFFFAOYSA-N 0.000 description 9
- 150000001408 amides Chemical class 0.000 description 9
- 125000000753 cycloalkyl group Chemical group 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 101001122499 Homo sapiens Nociceptin receptor Proteins 0.000 description 8
- 102100028646 Nociceptin receptor Human genes 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 108010020615 nociceptin receptor Proteins 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 230000035484 reaction time Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 150000001450 anions Chemical class 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- LIFZJFNOUKJNIN-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-(3-fluorophenyl)cyclohexyl]-n-(3-phenylpropyl)acetamide Chemical compound C1CC(N(C)C)(C=2C=C(F)C=CC=2)CCC1CC(=O)NCCCC1=CC=CC=C1 LIFZJFNOUKJNIN-UHFFFAOYSA-N 0.000 description 5
- LYUQWQRTDLVQGA-UHFFFAOYSA-N 3-phenylpropylamine Chemical compound NCCCC1=CC=CC=C1 LYUQWQRTDLVQGA-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 102000003840 Opioid Receptors Human genes 0.000 description 5
- 108090000137 Opioid Receptors Proteins 0.000 description 5
- AXJDEHNQPMZKOS-UHFFFAOYSA-N acetylazanium;chloride Chemical compound [Cl-].CC([NH3+])=O AXJDEHNQPMZKOS-UHFFFAOYSA-N 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 229940076279 serotonin Drugs 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
- MJVDUTFFYILLRR-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-(3-fluorophenyl)cyclohexyl]-n-[1-(1h-indol-3-yl)propan-2-yl]acetamide Chemical compound C=1NC2=CC=CC=C2C=1CC(C)NC(=O)CC(CC1)CCC1(N(C)C)C1=CC=CC(F)=C1 MJVDUTFFYILLRR-UHFFFAOYSA-N 0.000 description 4
- PWAWSBFYNQWNTC-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-(4-fluorophenyl)cyclohexyl]-n-(3-phenylpropyl)acetamide Chemical compound C1CC(N(C)C)(C=2C=CC(F)=CC=2)CCC1CC(=O)NCCCC1=CC=CC=C1 PWAWSBFYNQWNTC-UHFFFAOYSA-N 0.000 description 4
- KNPFHPQZFKZLTR-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-(4-fluorophenyl)cyclohexyl]-n-[2-(1h-indol-3-yl)ethyl]acetamide Chemical compound C1CC(CC(=O)NCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=C(F)C=C1 KNPFHPQZFKZLTR-UHFFFAOYSA-N 0.000 description 4
- IEBPFIGIRGCOBH-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexylidene]-n-[1-(1h-indol-3-yl)propan-2-yl]acetamide Chemical compound C=1NC2=CC=CC=C2C=1CC(C)NC(=O)C=C(CC1)CCC1(N(C)C)C1=CC=CC=C1 IEBPFIGIRGCOBH-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 108091006629 SLC13A2 Proteins 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- 229940035676 analgesics Drugs 0.000 description 4
- 239000000730 antalgic agent Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- FNIATMYXUPOJRW-UHFFFAOYSA-N cyclohexylidene Chemical group [C]1CCCCC1 FNIATMYXUPOJRW-UHFFFAOYSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000012280 lithium aluminium hydride Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 229960002748 norepinephrine Drugs 0.000 description 4
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000005051 trimethylchlorosilane Substances 0.000 description 4
- XBOGAFGECKZYCS-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-(3-fluorophenyl)cyclohexyl]-n-[2-(1h-indol-3-yl)ethyl]acetamide Chemical compound C1CC(CC(=O)NCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC(F)=C1 XBOGAFGECKZYCS-UHFFFAOYSA-N 0.000 description 3
- RNRVCLAMFBVDMM-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-(3-fluorophenyl)cyclohexylidene]acetic acid Chemical compound C=1C=CC(F)=CC=1C1(N(C)C)CCC(=CC(O)=O)CC1 RNRVCLAMFBVDMM-UHFFFAOYSA-N 0.000 description 3
- MCASMVMSMPGHEQ-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-(4-fluorophenyl)cyclohexylidene]acetic acid;hydrochloride Chemical compound Cl.C=1C=C(F)C=CC=1C1(N(C)C)CCC(=CC(O)=O)CC1 MCASMVMSMPGHEQ-UHFFFAOYSA-N 0.000 description 3
- WPUMKKPVELQILE-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]-n-(4-fluorophenyl)acetamide Chemical compound C1CC(N(C)C)(C=2C=CC=CC=2)CCC1CC(=O)NC1=CC=C(F)C=C1 WPUMKKPVELQILE-UHFFFAOYSA-N 0.000 description 3
- XIGQHSXQTFJKEY-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]-n-(4-methylphenyl)acetamide Chemical compound C1CC(N(C)C)(C=2C=CC=CC=2)CCC1CC(=O)NC1=CC=C(C)C=C1 XIGQHSXQTFJKEY-UHFFFAOYSA-N 0.000 description 3
- STQBAPCZGGFKQU-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]-n-[4-(1h-indol-3-yl)butyl]acetamide Chemical compound C1CC(CC(=O)NCCCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC=C1 STQBAPCZGGFKQU-UHFFFAOYSA-N 0.000 description 3
- ZVABSSHLAAYGJZ-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]-n-phenylacetamide Chemical compound C1CC(N(C)C)(C=2C=CC=CC=2)CCC1CC(=O)NC1=CC=CC=C1 ZVABSSHLAAYGJZ-UHFFFAOYSA-N 0.000 description 3
- ZHJQWCYMKFUVGG-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-pyridin-2-ylcyclohexyl]-n-(3-phenylpropyl)acetamide Chemical compound C1CC(N(C)C)(C=2N=CC=CC=2)CCC1CC(=O)NCCCC1=CC=CC=C1 ZHJQWCYMKFUVGG-UHFFFAOYSA-N 0.000 description 3
- HFNGUYMLYDVASX-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-pyridin-2-ylcyclohexyl]acetic acid Chemical compound C=1C=CC=NC=1C1(N(C)C)CCC(CC(O)=O)CC1 HFNGUYMLYDVASX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229960005181 morphine Drugs 0.000 description 3
- 229940127240 opiate Drugs 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 2
- NAOLWIGVYRIGTP-UHFFFAOYSA-N 1,3,5-trihydroxyanthracene-9,10-dione Chemical compound C1=CC(O)=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1 NAOLWIGVYRIGTP-UHFFFAOYSA-N 0.000 description 2
- FFFIRKXTFQCCKJ-UHFFFAOYSA-N 2,4,6-trimethylbenzoic acid Chemical compound CC1=CC(C)=C(C(O)=O)C(C)=C1 FFFIRKXTFQCCKJ-UHFFFAOYSA-N 0.000 description 2
- RUDUGHZJJURNDW-UHFFFAOYSA-N 2-[2-(dimethylamino)-4-phenylcyclohexylidene]-n-[2-(1h-indol-3-yl)ethyl]acetamide;hydrochloride Chemical compound Cl.C1CC(=CC(=O)NCCC=2C3=CC=CC=C3NC=2)C(N(C)C)CC1C1=CC=CC=C1 RUDUGHZJJURNDW-UHFFFAOYSA-N 0.000 description 2
- KQWQDBMUWDZLGV-UHFFFAOYSA-N 2-[4-(dimethylamino)-1-hydroxy-4-pyridin-2-ylcyclohexyl]acetic acid Chemical compound C=1C=CC=NC=1C1(N(C)C)CCC(O)(CC(O)=O)CC1 KQWQDBMUWDZLGV-UHFFFAOYSA-N 0.000 description 2
- APWOUSYVMVQXOB-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-(3-fluorophenyl)cyclohexylidene]-n-(3-phenylpropyl)acetamide Chemical compound C1CC(N(C)C)(C=2C=C(F)C=CC=2)CCC1=CC(=O)NCCCC1=CC=CC=C1 APWOUSYVMVQXOB-UHFFFAOYSA-N 0.000 description 2
- OBZIIWHAMWOGCE-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-(3-fluorophenyl)cyclohexylidene]-n-[2-(1h-indol-3-yl)ethyl]acetamide Chemical compound C1CC(=CC(=O)NCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC(F)=C1 OBZIIWHAMWOGCE-UHFFFAOYSA-N 0.000 description 2
- BNVWRXOVAGPUSY-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-(4-fluorophenyl)cyclohexylidene]-n-(3-phenylpropyl)acetamide Chemical compound C1CC(N(C)C)(C=2C=CC(F)=CC=2)CCC1=CC(=O)NCCCC1=CC=CC=C1 BNVWRXOVAGPUSY-UHFFFAOYSA-N 0.000 description 2
- DJROMQDFKLXMTG-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-(4-fluorophenyl)cyclohexylidene]-n-[1-(1h-indol-3-yl)propan-2-yl]acetamide Chemical compound C=1NC2=CC=CC=C2C=1CC(C)NC(=O)C=C(CC1)CCC1(N(C)C)C1=CC=C(F)C=C1 DJROMQDFKLXMTG-UHFFFAOYSA-N 0.000 description 2
- ULSQOMKUNMHFSX-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-(4-fluorophenyl)cyclohexylidene]-n-[2-(1h-indol-3-yl)ethyl]acetamide Chemical compound C1CC(=CC(=O)NCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=C(F)C=C1 ULSQOMKUNMHFSX-UHFFFAOYSA-N 0.000 description 2
- VDDCWMNKWHZOII-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]-n-(1h-indol-3-ylmethyl)acetamide;hydrochloride Chemical compound Cl.C1CC(CC(=O)NCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC=C1 VDDCWMNKWHZOII-UHFFFAOYSA-N 0.000 description 2
- IYTMBGXPIAXREO-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]-n-(4-methoxyphenyl)acetamide Chemical compound C1=CC(OC)=CC=C1NC(=O)CC1CCC(C=2C=CC=CC=2)(N(C)C)CC1 IYTMBGXPIAXREO-UHFFFAOYSA-N 0.000 description 2
- XWRCJCGSNNVMOO-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]-n-[1-(1h-indol-3-yl)propan-2-yl]acetamide Chemical compound C=1NC2=CC=CC=C2C=1CC(C)NC(=O)CC(CC1)CCC1(N(C)C)C1=CC=CC=C1 XWRCJCGSNNVMOO-UHFFFAOYSA-N 0.000 description 2
- GNZAXSLGCPJXTB-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]-n-[2-(1h-indol-3-yl)ethyl]acetamide Chemical compound C1CC(CC(=O)NCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC=C1 GNZAXSLGCPJXTB-UHFFFAOYSA-N 0.000 description 2
- JSLIQOHOAKMWJS-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]-n-[3-(1h-indol-3-yl)propyl]acetamide Chemical compound C1CC(CC(=O)NCCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC=C1 JSLIQOHOAKMWJS-UHFFFAOYSA-N 0.000 description 2
- RXHSBXUGAZDFAQ-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]-n-[5-(1h-indol-3-yl)pentyl]acetamide Chemical compound C1CC(CC(=O)NCCCCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC=C1 RXHSBXUGAZDFAQ-UHFFFAOYSA-N 0.000 description 2
- PSQPKAQWQPDVDL-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]-n-[6-(1h-indol-3-yl)hexyl]acetamide Chemical compound C1CC(CC(=O)NCCCCCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC=C1 PSQPKAQWQPDVDL-UHFFFAOYSA-N 0.000 description 2
- IAOICMRLWLDDCO-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexylidene]-n-(4-fluorophenyl)acetamide Chemical compound C1CC(N(C)C)(C=2C=CC=CC=2)CCC1=CC(=O)NC1=CC=C(F)C=C1 IAOICMRLWLDDCO-UHFFFAOYSA-N 0.000 description 2
- BHENYOXQCUUBNU-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexylidene]-n-[3-(1h-indol-3-yl)propyl]acetamide Chemical compound C1CC(=CC(=O)NCCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC=C1 BHENYOXQCUUBNU-UHFFFAOYSA-N 0.000 description 2
- LEOKEHQOMJIFDJ-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexylidene]-n-[4-(1h-indol-3-yl)butyl]acetamide Chemical compound C1CC(=CC(=O)NCCCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC=C1 LEOKEHQOMJIFDJ-UHFFFAOYSA-N 0.000 description 2
- KQGNHARGVRZDCF-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexylidene]-n-[5-(1h-indol-3-yl)pentyl]acetamide Chemical compound C1CC(=CC(=O)NCCCCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC=C1 KQGNHARGVRZDCF-UHFFFAOYSA-N 0.000 description 2
- BQSIZGBAPZAEMM-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexylidene]-n-[6-(1h-indol-3-yl)hexyl]acetamide Chemical compound C1CC(=CC(=O)NCCCCCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC=C1 BQSIZGBAPZAEMM-UHFFFAOYSA-N 0.000 description 2
- VIKBNMWOLLIQPG-UHFFFAOYSA-N 2-methyldecanedioic acid Chemical compound OC(=O)C(C)CCCCCCCC(O)=O VIKBNMWOLLIQPG-UHFFFAOYSA-N 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- AJHPGXZOIAYYDW-UHFFFAOYSA-N 3-(2-cyanophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC1=CC=CC=C1C#N AJHPGXZOIAYYDW-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-PZFLKRBQSA-N 4-amino-3,5-ditritiobenzoic acid Chemical compound [3H]c1cc(cc([3H])c1N)C(O)=O ALYNCZNDIQEVRV-PZFLKRBQSA-N 0.000 description 2
- OTCYOBLTAQTFPW-UHFFFAOYSA-N 4-aminocyclohexan-1-one Chemical class NC1CCC(=O)CC1 OTCYOBLTAQTFPW-UHFFFAOYSA-N 0.000 description 2
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 2
- AGNFWIZBEATIAK-UHFFFAOYSA-N 4-phenylbutylamine Chemical compound NCCCCC1=CC=CC=C1 AGNFWIZBEATIAK-UHFFFAOYSA-N 0.000 description 2
- NQKSUBMAEVZEKS-UHFFFAOYSA-N 5-(1h-indol-3-yl)pentanamide Chemical compound C1=CC=C2C(CCCCC(=O)N)=CNC2=C1 NQKSUBMAEVZEKS-UHFFFAOYSA-N 0.000 description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 2
- GSOQFCIVGOXYMC-UHFFFAOYSA-N 6-(1h-indol-3-yl)hexan-1-amine Chemical compound C1=CC=C2C(CCCCCCN)=CNC2=C1 GSOQFCIVGOXYMC-UHFFFAOYSA-N 0.000 description 2
- LTHQHGSPPIFXAW-UHFFFAOYSA-N 6-(1h-indol-3-yl)hexanamide Chemical compound C1=CC=C2C(CCCCCC(=O)N)=CNC2=C1 LTHQHGSPPIFXAW-UHFFFAOYSA-N 0.000 description 2
- RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 229910010084 LiAlH4 Inorganic materials 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- OKJIRPAQVSHGFK-UHFFFAOYSA-N N-acetylglycine Chemical compound CC(=O)NCC(O)=O OKJIRPAQVSHGFK-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- 229910006069 SO3H Inorganic materials 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 2
- 150000001399 aluminium compounds Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 229940077746 antacid containing aluminium compound Drugs 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000003637 basic solution Substances 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 150000001767 cationic compounds Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- GABJYIHTZAADQK-UHFFFAOYSA-N ethyl 2-[4-(dimethylamino)-4-phenylcyclohexyl]acetate Chemical compound C1CC(CC(=O)OCC)CCC1(N(C)C)C1=CC=CC=C1 GABJYIHTZAADQK-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- FYAQQULBLMNGAH-UHFFFAOYSA-N hexane-1-sulfonic acid Chemical compound CCCCCCS(O)(=O)=O FYAQQULBLMNGAH-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 2
- JXYGLMATGAAIBU-UHFFFAOYSA-N indol-3-ylmethylamine Chemical compound C1=CC=C2C(CN)=CNC2=C1 JXYGLMATGAAIBU-UHFFFAOYSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229910001411 inorganic cation Inorganic materials 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- BSHKTVSGDMNSOP-IJWOKDSUSA-N methyl (2s)-2-[[2-[4-(dimethylamino)-4-phenylcyclohexyl]acetyl]amino]-3-(1h-indol-3-yl)propanoate Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)OC)C(=O)CC(CC1)CCC1(N(C)C)C1=CC=CC=C1 BSHKTVSGDMNSOP-IJWOKDSUSA-N 0.000 description 2
- YGXXCZGXWASXIZ-XOMJIJKTSA-N methyl (2s)-2-[[2-[4-(dimethylamino)-4-phenylcyclohexyl]acetyl]amino]-3-(1h-indol-3-yl)propanoate;hydrochloride Chemical compound Cl.N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)OC)C(=O)CC(CC1)CCC1(N(C)C)C1=CC=CC=C1 YGXXCZGXWASXIZ-XOMJIJKTSA-N 0.000 description 2
- JTCIXBZJBANDOK-XOMJIJKTSA-N methyl (2s)-2-[[2-[4-(dimethylamino)-4-phenylcyclohexyl]acetyl]amino]-3-(1h-indol-3-yl)propanoate;potassium Chemical compound [K].N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)OC)C(=O)CC(CC1)CCC1(N(C)C)C1=CC=CC=C1 JTCIXBZJBANDOK-XOMJIJKTSA-N 0.000 description 2
- XNFNGGQRDXFYMM-PPHPATTJSA-N methyl (2s)-2-amino-3-(1h-indol-3-yl)propanoate;hydrochloride Chemical compound Cl.C1=CC=C2C(C[C@H](N)C(=O)OC)=CNC2=C1 XNFNGGQRDXFYMM-PPHPATTJSA-N 0.000 description 2
- KXAVTKXQYDXTCT-UHFFFAOYSA-N methyl 2-[4-(dimethylamino)-4-phenylcyclohexyl]acetate;hydrochloride Chemical compound Cl.C1CC(CC(=O)OC)CCC1(N(C)C)C1=CC=CC=C1 KXAVTKXQYDXTCT-UHFFFAOYSA-N 0.000 description 2
- MERSZGSXTCRBDG-UHFFFAOYSA-N methyl 2-[4-(dimethylamino)-4-phenylcyclohexylidene]acetate;hydrochloride Chemical compound Cl.C1CC(=CC(=O)OC)CCC1(N(C)C)C1=CC=CC=C1 MERSZGSXTCRBDG-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229960004127 naloxone Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 2
- 125000000565 sulfonamide group Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000003568 synaptosome Anatomy 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229960004380 tramadol Drugs 0.000 description 2
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- KSSBNFJTUAHFJV-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-[4-(dimethylamino)-4-phenylcyclohexylidene]acetate Chemical compound C1CC(N(C)C)(C=2C=CC=CC=2)CCC1=CC(=O)ON1C(=O)CCC1=O KSSBNFJTUAHFJV-UHFFFAOYSA-N 0.000 description 1
- IIFVWLUQBAIPMJ-UHFFFAOYSA-N (4-fluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C=C1 IIFVWLUQBAIPMJ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- CKLFJWXRWIQYOC-UHFFFAOYSA-N 2-(4-fluorophenyl)ethanamine Chemical compound NCCC1=CC=C(F)C=C1 CKLFJWXRWIQYOC-UHFFFAOYSA-N 0.000 description 1
- VDEDWCRVFCQZCO-UHFFFAOYSA-N 2-[2-(dimethylamino)-4-phenylcyclohexylidene]-n-[2-(1h-indol-3-yl)ethyl]acetamide Chemical compound C1CC(=CC(=O)NCCC=2C3=CC=CC=C3NC=2)C(N(C)C)CC1C1=CC=CC=C1 VDEDWCRVFCQZCO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- KCIOTZNIJIPFON-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-(3-fluorophenyl)cyclohexylidene]-n-[1-(1h-indol-3-yl)propan-2-yl]acetamide;hydrochloride Chemical compound Cl.C=1NC2=CC=CC=C2C=1CC(C)NC(=O)C=C(CC1)CCC1(N(C)C)C1=CC=CC(F)=C1 KCIOTZNIJIPFON-UHFFFAOYSA-N 0.000 description 1
- LRPFAOYGKKOMLV-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]-N-(4-methoxyphenyl)acetamide 2-[4-(dimethylamino)-4-phenylcyclohexyl]-N-(4-methylphenyl)acetamide dihydrochloride Chemical compound Cl.CN(C1(CCC(CC1)CC(=O)NC1=CC=C(C=C1)OC)C1=CC=CC=C1)C.Cl.CN(C1(CCC(CC1)CC(=O)NC1=CC=C(C=C1)C)C1=CC=CC=C1)C LRPFAOYGKKOMLV-UHFFFAOYSA-N 0.000 description 1
- YHPXJTGWGMBXSV-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]-n-(1h-indol-3-ylmethyl)acetamide Chemical compound C1CC(CC(=O)NCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC=C1 YHPXJTGWGMBXSV-UHFFFAOYSA-N 0.000 description 1
- SHEPDRQFPMZARJ-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]-n-(2-phenylethyl)acetamide Chemical compound C1CC(N(C)C)(C=2C=CC=CC=2)CCC1CC(=O)NCCC1=CC=CC=C1 SHEPDRQFPMZARJ-UHFFFAOYSA-N 0.000 description 1
- OOQCEGHEPLEHBR-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]-n-(3-phenylpropyl)acetamide Chemical compound C1CC(N(C)C)(C=2C=CC=CC=2)CCC1CC(=O)NCCCC1=CC=CC=C1 OOQCEGHEPLEHBR-UHFFFAOYSA-N 0.000 description 1
- IRJYVPBUAJAONT-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]-n-(4-fluorophenyl)acetamide;hydrochloride Chemical compound Cl.C1CC(N(C)C)(C=2C=CC=CC=2)CCC1CC(=O)NC1=CC=C(F)C=C1 IRJYVPBUAJAONT-UHFFFAOYSA-N 0.000 description 1
- PROHEZYFXPIGLK-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexyl]-n-(4-phenylbutyl)acetamide Chemical compound C1CC(N(C)C)(C=2C=CC=CC=2)CCC1CC(=O)NCCCCC1=CC=CC=C1 PROHEZYFXPIGLK-UHFFFAOYSA-N 0.000 description 1
- JRWONGMVXXKYNC-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexylidene]-n-(1h-indol-3-ylmethyl)acetamide Chemical compound C1CC(=CC(=O)NCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC=C1 JRWONGMVXXKYNC-UHFFFAOYSA-N 0.000 description 1
- GYTDPNNCIGLBGQ-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexylidene]-n-(2-phenylethyl)acetamide Chemical compound C1CC(N(C)C)(C=2C=CC=CC=2)CCC1=CC(=O)NCCC1=CC=CC=C1 GYTDPNNCIGLBGQ-UHFFFAOYSA-N 0.000 description 1
- KEJUDUNBXBIFLD-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexylidene]-n-(3-phenylpropyl)acetamide Chemical compound C1CC(N(C)C)(C=2C=CC=CC=2)CCC1=CC(=O)NCCCC1=CC=CC=C1 KEJUDUNBXBIFLD-UHFFFAOYSA-N 0.000 description 1
- CKVQERZYJKAPNS-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexylidene]-n-(4-phenylbutyl)acetamide Chemical compound C1CC(N(C)C)(C=2C=CC=CC=2)CCC1=CC(=O)NCCCCC1=CC=CC=C1 CKVQERZYJKAPNS-UHFFFAOYSA-N 0.000 description 1
- WGDVJTWVUJBWOU-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexylidene]-n-[(4-fluorophenyl)methyl]acetamide Chemical compound C1CC(N(C)C)(C=2C=CC=CC=2)CCC1=CC(=O)NCC1=CC=C(F)C=C1 WGDVJTWVUJBWOU-UHFFFAOYSA-N 0.000 description 1
- BXRJNMBVFMYEBK-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-phenylcyclohexylidene]acetic acid Chemical compound C=1C=CC=CC=1C1(N(C)C)CCC(=CC(O)=O)CC1 BXRJNMBVFMYEBK-UHFFFAOYSA-N 0.000 description 1
- VWOPHBLIBZRRPH-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-pyridin-2-ylcyclohexyl]-n-[2-(1h-indol-3-yl)ethyl]acetamide Chemical compound C1CC(CC(=O)NCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC=N1 VWOPHBLIBZRRPH-UHFFFAOYSA-N 0.000 description 1
- WJSMFZBYDQFHNO-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-pyridin-2-ylcyclohexylidene]-n-(3-phenylpropyl)acetamide Chemical compound C1CC(N(C)C)(C=2N=CC=CC=2)CCC1=CC(=O)NCCCC1=CC=CC=C1 WJSMFZBYDQFHNO-UHFFFAOYSA-N 0.000 description 1
- SFBPXOXSRAWLPZ-UHFFFAOYSA-N 2-[4-(dimethylamino)-4-pyridin-2-ylcyclohexylidene]-n-[2-(1h-indol-3-yl)ethyl]acetamide Chemical compound C1CC(=CC(=O)NCCC=2C3=CC=CC=C3NC=2)CCC1(N(C)C)C1=CC=CC=N1 SFBPXOXSRAWLPZ-UHFFFAOYSA-N 0.000 description 1
- DKLQJNUJPSHYQG-UHFFFAOYSA-N 2-cyclohexylacetamide Chemical class NC(=O)CC1CCCCC1 DKLQJNUJPSHYQG-UHFFFAOYSA-N 0.000 description 1
- HPTFRRHUFYPYNB-UHFFFAOYSA-N 2-cyclohexylideneacetamide Chemical class NC(=O)C=C1CCCCC1 HPTFRRHUFYPYNB-UHFFFAOYSA-N 0.000 description 1
- OOIAXMPVZJKJHK-UHFFFAOYSA-N 3-(1h-indol-3-yl)propan-1-amine Chemical compound C1=CC=C2C(CCCN)=CNC2=C1 OOIAXMPVZJKJHK-UHFFFAOYSA-N 0.000 description 1
- GZQBGZWAALHNBW-UHFFFAOYSA-N 4-(1h-indol-3-yl)butan-1-amine Chemical compound C1=CC=C2C(CCCCN)=CNC2=C1 GZQBGZWAALHNBW-UHFFFAOYSA-N 0.000 description 1
- DEOPEYZZVGZQFC-UHFFFAOYSA-N 4-(dimethylamino)-4-phenylcyclohexan-1-one Chemical compound C=1C=CC=CC=1C1(N(C)C)CCC(=O)CC1 DEOPEYZZVGZQFC-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- OSQJMBHMUWMCDX-UHFFFAOYSA-N 5-(1h-indol-3-yl)pentan-1-amine Chemical compound C1=CC=C2C(CCCCCN)=CNC2=C1 OSQJMBHMUWMCDX-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- SZWFMSFEGSZZOQ-UHFFFAOYSA-N Cl.CN(C1(CCC(CC1)=CC(=O)O)C1=CC=CC=C1)C.O=C1N(C(CC1)=O)OC(C=C1CCC(CC1)(C1=CC=CC=C1)N(C)C)=O Chemical compound Cl.CN(C1(CCC(CC1)=CC(=O)O)C1=CC=CC=C1)C.O=C1N(C(CC1)=O)OC(C=C1CCC(CC1)(C1=CC=CC=C1)N(C)C)=O SZWFMSFEGSZZOQ-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- NCIKQJBVUNUXLW-UHFFFAOYSA-N N-methyltryptamine Chemical compound C1=CC=C2C(CCNC)=CNC2=C1 NCIKQJBVUNUXLW-UHFFFAOYSA-N 0.000 description 1
- FTBZYYPQRJHYPS-UHFFFAOYSA-N N1C=C(C2=CC=CC=C12)CCCCCC(=O)O.C(#N)COC(CCCCCC1=CNC2=CC=CC=C12)=O Chemical compound N1C=C(C2=CC=CC=C12)CCCCCC(=O)O.C(#N)COC(CCCCCC1=CNC2=CC=CC=C12)=O FTBZYYPQRJHYPS-UHFFFAOYSA-N 0.000 description 1
- 229910003849 O-Si Inorganic materials 0.000 description 1
- 229910003872 O—Si Inorganic materials 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 1
- 238000001720 action spectrum Methods 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000005219 aminonitrile group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- YETIZZXMDZUMEN-UHFFFAOYSA-N cyanomethyl 5-(1h-indol-3-yl)pentanoate Chemical compound C1=CC=C2C(CCCCC(=O)OCC#N)=CNC2=C1 YETIZZXMDZUMEN-UHFFFAOYSA-N 0.000 description 1
- BIWLSAAJULMOKA-UHFFFAOYSA-N cyanomethyl 6-(1h-indol-3-yl)hexanoate Chemical compound C1=CC=C2C(CCCCCC(=O)OCC#N)=CNC2=C1 BIWLSAAJULMOKA-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical class OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- 150000001934 cyclohexanes Chemical class 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000004212 difluorophenyl group Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000005469 ethylenyl group Chemical group 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- UYXAWHWODHRRMR-UHFFFAOYSA-N hexobarbital Chemical compound O=C1N(C)C(=O)NC(=O)C1(C)C1=CCCCC1 UYXAWHWODHRRMR-UHFFFAOYSA-N 0.000 description 1
- 229960002456 hexobarbital Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- KDFBGNBTTMPNIG-UHFFFAOYSA-N hydron;2-(1h-indol-3-yl)ethanamine;chloride Chemical compound Cl.C1=CC=C2C(CCN)=CNC2=C1 KDFBGNBTTMPNIG-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- KCUNTYMNJVXYKZ-JTQLQIEISA-N methyl (2s)-2-amino-3-(1h-indol-3-yl)propanoate Chemical compound C1=CC=C2C(C[C@H](N)C(=O)OC)=CNC2=C1 KCUNTYMNJVXYKZ-JTQLQIEISA-N 0.000 description 1
- RTMVDWLKGAZFCP-UHFFFAOYSA-N methyl 2-[[2-[4-(dimethylamino)-4-phenylcyclohexylidene]acetyl]amino]-3-(1h-indol-3-yl)propanoate Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)OC)NC(=O)C=C(CC1)CCC1(N(C)C)C1=CC=CC=C1 RTMVDWLKGAZFCP-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000036453 micturition reflex Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- NWJUMMHVDMNYMJ-UHFFFAOYSA-N n-benzyl-1,1,1-trifluoromethanamine Chemical compound FC(F)(F)NCC1=CC=CC=C1 NWJUMMHVDMNYMJ-UHFFFAOYSA-N 0.000 description 1
- KNTPZTDIOYUBJC-UHFFFAOYSA-N n-benzyl-2-[4-(dimethylamino)-4-phenylcyclohexylidene]acetamide Chemical compound C1CC(N(C)C)(C=2C=CC=CC=2)CCC1=CC(=O)NCC1=CC=CC=C1 KNTPZTDIOYUBJC-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 230000000966 norepinephrine reuptake Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- RZXMPPFPUUCRFN-UHFFFAOYSA-N p-toluidine Chemical compound CC1=CC=C(N)C=C1 RZXMPPFPUUCRFN-UHFFFAOYSA-N 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000006238 prop-1-en-1-yl group Chemical group [H]\C(*)=C(/[H])C([H])([H])[H] 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 230000013275 serotonin uptake Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004023507A DE102004023507A1 (de) | 2004-05-10 | 2004-05-10 | Substituierte Cyclohexylessigsäure-Derivate |
| DE102004023507.4 | 2004-05-10 | ||
| PCT/EP2005/004909 WO2005110976A1 (de) | 2004-05-10 | 2005-05-06 | Substituierte cyclohexylessigsäure-derivate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2563017A1 CA2563017A1 (en) | 2005-11-24 |
| CA2563017C true CA2563017C (en) | 2012-10-02 |
Family
ID=34968613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2563017A Expired - Fee Related CA2563017C (en) | 2004-05-10 | 2005-05-06 | Substituted cyclohexylacetic acid derivatives |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8017630B2 (https=) |
| EP (1) | EP1751093B1 (https=) |
| JP (1) | JP4852536B2 (https=) |
| AT (1) | ATE483679T1 (https=) |
| CA (1) | CA2563017C (https=) |
| CY (1) | CY1111327T1 (https=) |
| DE (2) | DE102004023507A1 (https=) |
| DK (1) | DK1751093T3 (https=) |
| ES (1) | ES2353390T3 (https=) |
| PL (1) | PL1751093T3 (https=) |
| PT (1) | PT1751093E (https=) |
| SI (1) | SI1751093T1 (https=) |
| WO (1) | WO2005110976A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090215725A1 (en) * | 2008-02-26 | 2009-08-27 | Grunenthal Gmbh | Substituted 4-aminocyclohexane derivatives |
| ES2375543T3 (es) | 2008-03-27 | 2012-03-01 | Grünenthal GmbH | Derivados de espiro(5.5)undecano. |
| CN102046591B (zh) | 2008-03-27 | 2014-12-03 | 格吕伦塔尔有限公司 | 羟甲基环己胺 |
| AU2009228647B2 (en) | 2008-03-27 | 2013-07-04 | Grunenthal Gmbh | Substituted spirocyclic cyclohexane derivatives |
| ES2464102T3 (es) | 2008-03-27 | 2014-05-30 | Grünenthal GmbH | Derivados de 4-aminociclohexano sustituidos |
| JP5529843B2 (ja) | 2008-03-27 | 2014-06-25 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 置換シクロヘキシルジアミン |
| EP2280941B1 (de) | 2008-03-27 | 2015-05-06 | Grünenthal GmbH | (hetero-)aryl-cyclohexan-derivate |
| US20090298834A1 (en) * | 2008-06-02 | 2009-12-03 | Hassan Pajouhesh | 4-(aminomethyl)cyclohexanamine derivatives as calcium channel blockers |
| RS55943B1 (sr) | 2013-06-24 | 2017-09-29 | Merck Patent Gmbh | Ftalazin derivati |
| CN106535884A (zh) | 2014-06-06 | 2017-03-22 | 弗雷克萨斯生物科学公司 | 免疫调节剂 |
| MX2017005462A (es) * | 2014-11-05 | 2017-07-28 | Flexus Biosciences Inc | Agentes inmunorreguladores. |
| UY36391A (es) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
| UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| CN114340670B (zh) | 2019-07-11 | 2026-02-17 | 普拉克西斯精密药物股份有限公司 | T-型钙通道调节剂的制剂及其使用方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4115589A (en) * | 1977-05-17 | 1978-09-19 | The Upjohn Company | Compounds, compositions and method of use |
| US4366172A (en) * | 1977-09-29 | 1982-12-28 | The Upjohn Company | 4-Amino-cyclohexanols, their pharmaceutical compositions and methods of use |
| US4212878A (en) * | 1978-01-26 | 1980-07-15 | The Upjohn Company | Phenylacetamide derivative analgesics |
| US4346101A (en) * | 1980-12-08 | 1982-08-24 | The Upjohn Company | Benzamide derivative analgesics |
| DE3924304A1 (de) * | 1989-07-22 | 1991-01-31 | Bayer Ag | Neue fluorierte cyclohexanderivate, verfahren und zwischenprodukte zu deren herstellung und die verwendung der neuen fluorierten cyclohexanderivate als fungizide und zwischenprodukte |
| US5304479A (en) * | 1991-12-06 | 1994-04-19 | Diagnostic Reagents, Inc. | Phencyclidine compounds and assays for its determination |
| US5239110A (en) * | 1992-12-30 | 1993-08-24 | Sterling Winthrop, Inc. | Phenylcyclohexanol derivatives as agents for treating CNS disorders |
| CA2373855A1 (en) * | 1999-05-12 | 2000-11-23 | Solvay Pharmaceuticals B.V. | Method of treating psychotic disorders |
| DE19939044A1 (de) | 1999-08-18 | 2001-03-15 | Gruenenthal Gmbh | Verwendung von Morphinanderivaten als Arzneimittel |
| DE19963175A1 (de) | 1999-12-27 | 2001-07-12 | Gruenenthal Gmbh | Verwendung von substituierten 4-Amino-1-phenylbutan-2-ol-Verbindungen als Arzneimittel |
| GB0012240D0 (en) * | 2000-05-19 | 2000-07-12 | Merck Sharp & Dohme | Therapeutic agents |
| US7138397B2 (en) * | 2000-10-06 | 2006-11-21 | Tanabe Seiyaku Co., Ltd. | Nitrogenous 5-membered ring compounds |
| ES2188344B1 (es) * | 2000-11-29 | 2004-09-16 | Laboratorios Vita, S.A. | Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos. |
| DE10123163A1 (de) * | 2001-05-09 | 2003-01-16 | Gruenenthal Gmbh | Substituierte Cyclohexan-1,4-diaminderivate |
| EP1458704A1 (en) * | 2001-12-21 | 2004-09-22 | H. Lundbeck A/S | Aminoindane derivatives as serotonin and norepinephrine uptake inhibitors |
| US6818772B2 (en) * | 2002-02-22 | 2004-11-16 | Abbott Laboratories | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor |
| AU2003221178B2 (en) * | 2002-03-28 | 2006-06-15 | Tanabe Seiyaku Co., Ltd. | Benzofuran derivative |
| JP4329382B2 (ja) * | 2002-04-04 | 2009-09-09 | 田辺三菱製薬株式会社 | 医薬組成物 |
| WO2004022535A1 (ja) * | 2002-08-28 | 2004-03-18 | Yamanouchi Pharmaceutical Co., Ltd. | アクリルアミド誘導体 |
| DE10252666A1 (de) * | 2002-11-11 | 2004-08-05 | Grünenthal GmbH | N-Piperidyl-cyclohexan-Derivate |
| DE10252650A1 (de) * | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Cyclohexyl-Harnstoff-Derivate |
| WO2006040646A1 (en) * | 2004-10-14 | 2006-04-20 | Pfizer, Inc. | Benzimidazole or indole amides as inhibitors of pin1 |
-
2004
- 2004-05-10 DE DE102004023507A patent/DE102004023507A1/de not_active Withdrawn
-
2005
- 2005-05-06 DK DK05745355.7T patent/DK1751093T3/da active
- 2005-05-06 ES ES05745355T patent/ES2353390T3/es not_active Expired - Lifetime
- 2005-05-06 PL PL05745355T patent/PL1751093T3/pl unknown
- 2005-05-06 SI SI200531192T patent/SI1751093T1/sl unknown
- 2005-05-06 CA CA2563017A patent/CA2563017C/en not_active Expired - Fee Related
- 2005-05-06 DE DE502005010342T patent/DE502005010342D1/de not_active Expired - Lifetime
- 2005-05-06 JP JP2007512029A patent/JP4852536B2/ja not_active Expired - Fee Related
- 2005-05-06 PT PT05745355T patent/PT1751093E/pt unknown
- 2005-05-06 EP EP05745355A patent/EP1751093B1/de not_active Expired - Lifetime
- 2005-05-06 AT AT05745355T patent/ATE483679T1/de active
- 2005-05-06 WO PCT/EP2005/004909 patent/WO2005110976A1/de not_active Ceased
-
2006
- 2006-11-09 US US11/594,945 patent/US8017630B2/en not_active Expired - Fee Related
-
2010
- 2010-11-24 CY CY20101101057T patent/CY1111327T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007536319A (ja) | 2007-12-13 |
| US20070129347A1 (en) | 2007-06-07 |
| ES2353390T3 (es) | 2011-03-01 |
| EP1751093B1 (de) | 2010-10-06 |
| EP1751093A1 (de) | 2007-02-14 |
| US8017630B2 (en) | 2011-09-13 |
| WO2005110976A1 (de) | 2005-11-24 |
| PT1751093E (pt) | 2010-11-29 |
| DE502005010342D1 (en) | 2010-11-18 |
| CA2563017A1 (en) | 2005-11-24 |
| JP4852536B2 (ja) | 2012-01-11 |
| CY1111327T1 (el) | 2015-08-05 |
| DK1751093T3 (da) | 2010-12-20 |
| SI1751093T1 (sl) | 2011-01-31 |
| ATE483679T1 (de) | 2010-10-15 |
| PL1751093T3 (pl) | 2011-04-29 |
| DE102004023507A1 (de) | 2005-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2563017C (en) | Substituted cyclohexylacetic acid derivatives | |
| ES2482108T3 (es) | Hidroximetilciclohexilaminas | |
| ZA200504725B (en) | Sipirocyclic cyclohexane derivatives | |
| NZ529147A (en) | Substituted cyclohexane-1,4-diamine derivatives | |
| JP4982357B2 (ja) | ヘテロアリール−置換されたシクロヘキシル−1,4−ジアミン誘導体 | |
| ES2544488T3 (es) | Derivados de (hetero)aril-ciclohexano | |
| CA2566297C (en) | Substituted cyclohexyl-1,4-diamine derivatives | |
| CA2566215C (en) | Cyclohexyl-1,4-diamines substituted by acid derivatives | |
| CA2562539C (en) | Substituted cyclohexylcarboxylic acid derivatives | |
| JP4896009B2 (ja) | オキソ置換されたシクロヘキシル−1,4−ジアミンの酸誘導体 | |
| JP5037336B2 (ja) | 鎖長が延ばされ、置換されたシクロヘキシル−1,4−ジアミンの酸誘導体 | |
| NZ531112A (en) | Substituted 4-aminocyclohexanol derivatives | |
| JP6490187B2 (ja) | 置換アザスピロ(4.5)デカン誘導体 | |
| IL207753A (en) | Transformed history of 4-aminocyclohexane, a method of preparation and medicinal products containing them for the treatment of pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20170510 |